Publications by authors named "Henrik Schnack"
Article Synopsis
- The study aimed to determine the most cost-effective sequence of anti-IL17 treatments for moderate-to-severe plaque psoriasis in Italy and Germany over five years.
- Researchers adapted a treatment model to include real-world data on drug discontinuation rates and specific costs for the four available anti-IL17 biologics, using long-term efficacy measures to evaluate effectiveness.
- The findings indicated that the best treatment sequence is starting with brodalumab, followed by bimekizumab, ixekizumab, and finally secukinumab, resulting in a total cost-per-responder of €128,200 in Italy and €138,212 in Germany.
Article Synopsis
- * A cost per responder model was created, comparing treatments like brodalumab, ixekizumab, and adalimumab, based on their effectiveness measured through the Psoriasis Area and Severity Index (PASI).
- * Results indicated brodalumab was the most cost-effective option, showing the lowest costs per PASI100-responder in both countries and outperforming other biologics in the same category as well.
Background: A new 20-valent pneumococcal conjugate vaccine (PCV20) provides protection against 20 pneumococcal serotypes. The vaccine has the potential to decrease the impact of pneumococcal diseases in society and to increase health among vulnerable persons.
Aim: This study investigates the cost-effectiveness of vaccinating Danish adults in different age groups and risk of pneumococcal disease with PCV20 compared to the 23-valent pneumococcal polysaccharide vaccine (PPV23) - either as PCV20 compared to PPV23 or as PPV23 followed by PCV20 compared to PPV23.